Is methyl folate better than folic acid?

The short answer

Evidence tier: 1 — the central pregnancy conclusion rests on randomized outcome trials and a grade A USPSTF recommendation.

L-methylfolate is the active form of folate your body circulates, and it raises blood folate at least as well as folic acid, but folic acid is still the form official bodies recommend before and during pregnancy. That is because the large trials that proved folate prevents neural tube defects used folic acid. Common MTHFR variants do not stop people processing folic acid, according to the CDC. Methylfolate matters most in narrower situations, discussed with a physician.

The main points:

• Both forms raise folate status; methylfolate skips a conversion step.
• Only folic acid has outcome trials showing fewer neural tube defects.
• US guidance (USPSTF, CDC) recommends 400–800 µg of folic acid for anyone who could become pregnant, including people with MTHFR variants.
• High folic acid intakes can hide vitamin B12 deficiency, which is a reason to check B12, not a reason to fear folic acid at normal doses.

What is the difference between methylfolate and folic acid?

Evidence tier: 2 — pharmacokinetic reviews and a randomized comparison trial.

Folic acid is a synthetic, stable form of vitamin B9 used in supplements and fortified foods. It has no activity until the body reduces it, through several enzyme steps, to tetrahydrofolate and then to 5-methyltetrahydrofolate (5-MTHF). L-methylfolate, sold as calcium salts such as Metafolin, is that end product, and it is the main form of folate normally found in blood (Pietrzik et al., 2010).

At equal molar doses, the two have comparable absorption and bioavailability, and methylfolate is at least as effective at raising blood folate and lowering homocysteine, according to the same review. In a 24-week randomized trial in 144 women aged 19–33, red blood cell folate rose more with 416 µg of methylfolate per day than with 400 µg of folic acid (Lamers et al., 2006).

Does MTHFR mean you need methylfolate?

Evidence tier: 2 — current CDC guidance, with a dissenting expert review.

MTHFR is the enzyme that makes the final conversion to 5-MTHF. Common variants such as C677T reduce its activity, and this is the main reason methylfolate is marketed to people who have had genetic tests. Our MTHFR variants guide covers the genetics in more detail.

The CDC's position, updated in July 2026, is direct: people with an MTHFR variant can process all types of folate, including folic acid, and common variants are not a reason to avoid it (CDC, 2026). The CDC calls the idea that these people need 5-MTHF instead a misconception and does not recommend testing for common variants.

Some researchers disagree in emphasis. A 2013 review argued that people vary widely in how well they reduce folic acid and that carriers of certain variants may benefit more from 5-MTHF (Obeid et al., 2013). That is a reasoned argument based on biomarkers, not on outcome trials.

Should you take methylfolate or folic acid in pregnancy?

Evidence tier: 1 — randomized outcome trials and a grade A USPSTF recommendation.

The evidence that folate prevents neural tube defects, such as spina bifida, comes from folic acid. In the MRC Vitamin Study, 1,817 women who had had a previous affected pregnancy were randomized; folic acid gave a 72% protective effect against recurrence (MRC Vitamin Study Research Group, 1991). In a Hungarian trial of women planning a pregnancy, a multivitamin containing 0.8 mg of folic acid was followed by no neural tube defects, compared with six in the control group (Czeizel and Dudás, 1992).

Population data point the same way. Since 1998 the US has required enriched cereal grain products to carry folic acid, at 140 µg per 100 g. Birth defect surveillance across 19 US programs estimated that this prevents about 1,326 neural tube defect-affected births a year (Williams et al., 2015).

On that basis, the US Preventive Services Task Force reaffirmed in 2023 that everyone planning to or able to become pregnant should take a daily supplement containing 0.4 to 0.8 mg (400–800 µg) of folic acid, a grade A recommendation (USPSTF, 2023). The CDC says the 400 µg advice applies even with an MTHFR variant.

A 2026 review that favored methylfolate in several settings still concluded that folic acid remains the only folate form with proven efficacy in large randomized trials for preventing neural tube defects (Skavinska et al., 2026). Some prenatal products contain methylfolate instead, and it raises folate status well, but it has not been tested against birth defects as an outcome. Choosing a prenatal is a decision to make with your obstetrician or midwife.

How do you read folate on a supplement label?

Evidence tier: 2 — EFSA scientific opinions on folate conversion factors and upper intake levels.

Labels can make two products with the same amount of folate look different. Points to check:

• The unit. US labels give folate in micrograms of dietary folate equivalents (DFE), a unit that adjusts for the fact that folic acid is absorbed better than food folate. The folic acid amount is usually shown in brackets.
• A worked example. Folic acid counts as 1.7 µg DFE per microgram, so 400 µg of folic acid appears as 680 µg DFE. For methylfolate, EFSA proposed the same 1.7 factor below 400 µg per day and a factor of 2.0 at 400 µg or more, because it was found to be more bioavailable at that level (EFSA NDA Panel, 2022). Under EFSA's equations, 400 µg of methylfolate counts as 800 µg DFE.
• The form. "L-methylfolate", "(6S)-5-MTHF", calcium L-methylfolate and the glucosamine salt (sold as Quatrefolic) all describe the active form. Folinic acid is a different compound.
• The total from all products. EFSA's upper level for adults, including in pregnancy, is 1,000 µg per day, and it applies to folic acid and methylfolate salts combined (EFSA NDA Panel, 2023). A prenatal plus a B-complex plus fortified foods can add up. Natural food folate does not count toward that limit.

Can folic acid mask vitamin B12 deficiency?

Evidence tier: 3 — historical clinical observations and correlational studies, as described in recent reviews.

Yes, at high doses. In the 1940s and 1950s, doses above 5 mg per day were used to reverse the anemia of B12 deficiency. This hid the underlying deficiency while nerve damage could continue, and possibly worsened it (Miller et al., 2024). The authors note that evidence for active worsening is mainly correlational, but advise extra vigilance for B12 deficiency in older adults, people with absorption problems, and vegans or vegetarians taking high-dose folic acid.

EFSA used this same effect, the progression of nerve symptoms in people with B12 deficiency, as the basis for its upper level (EFSA NDA Panel, 2023). Reviews suggest methylfolate may carry less masking potential (Pietrzik et al., 2010), and one review states folic acid above 1,000 µg per day calls for monitoring (Skavinska et al., 2026). Whichever form you take, the practical safeguard is the same: know your B12 status.

Is unmetabolized folic acid a concern?

Evidence tier: 3 — national cross-sectional blood data and an EFSA systematic review; no outcome trials.

Some folic acid reaches the blood before the body has converted it. In US national survey samples from 2007–2008, unmetabolized folic acid was detectable in more than 95% of people, whether or not they took supplements, in a population where fortification is mandatory (Pfeiffer et al., 2015). Higher levels went with higher total folic acid intake and with not having fasted.

This finding is often used to argue for methylfolate, which does not leave unmetabolized folic acid behind. What is missing is evidence of harm. EFSA's 2023 review found the evidence insufficient to conclude that folate intake causes cognitive decline, colorectal cancer or prostate cancer. Unmetabolized folic acid is a reasonable research question, not a demonstrated risk.

When does methylfolate make sense?

Evidence tier: 3 — mixed evidence, from randomized psychiatric trials to pharmacological reasoning.

Situations where methylfolate is discussed include:

• Depression alongside antidepressants: in two trials in people with SSRI-resistant depression, adding 15 mg per day of L-methylfolate improved response in the second trial, while the first trial, which started at 7.5 mg, found no difference (Papakostas et al., 2012). These are prescription-level doses, far above nutritional intakes.
• Drugs that block folate conversion: methotrexate, trimethoprim and pyrimethamine inhibit dihydrofolate reductase, the enzyme folic acid needs. A review notes methylfolate may interact less with these medicines (Pietrzik et al., 2010).
• Personal preference outside pregnancy, where either form raises folate status.

Medicines change the picture in both directions. In people taking low-dose methotrexate for rheumatoid arthritis, a Cochrane review of six trials found that folic or folinic acid reduced gastrointestinal side effects, liver enzyme rises and treatment withdrawal, without reducing methotrexate's benefit (Shea et al., 2013). That evidence is for folic and folinic acid, not methylfolate. In pregnancy, a case-control study linked dihydrofolate reductase inhibitors and some antiepileptic drugs to more birth defects. Multivitamins containing folic acid reduced the excess risk with the first group but not with antiepileptics (Hernández-Díaz et al., 2000).

In each case, the form and amount belong with the prescribing physician. Switching forms on your own can undo a plan built around a specific drug.

Limitations

This is an educational guide, not medical advice.

• We read abstracts and official guidance, not full trial reports.
• Guidance here is US-based (USPSTF, CDC); other countries' advice may differ in dose.
• No head-to-head trial compares methylfolate and folic acid on neural tube defects, so their equivalence for that outcome is unknown.
• Methylfolate's lower B12-masking potential is argued from mechanism and reviews, not from outcome trials.

The bottom line

Methylfolate is a well-absorbed, active form of folate, and for most uses it works at least as well as folic acid at raising folate levels. For pregnancy, though, folic acid is the form with randomized evidence against neural tube defects, and US guidance recommends it for anyone who could become pregnant, MTHFR variant or not. The case for methylfolate is strongest in specific clinical situations, such as adjunctive depression treatment, that call for a physician's input. Whatever you take, keep an eye on vitamin B12.

Related on this site

• MTHFR variants and peptide therapy
• Pharmacogenomics and peptide therapy
• Personal genomics services compared
• Peptides in pregnancy and breastfeeding
• GLP-1s, contraception and pregnancy planning
• Labs before and during peptides
• Peptides for women
• Women's health pillar

References

• Pietrzik K, Bailey L, Shane B. 2010. Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. PMID 20608755
• Lamers Y, Prinz-Langenohl R, Brämswig S, et al. 2006. Red blood cell folate concentrations increase more after supplementation with [6S]-5-methyltetrahydrofolate than with folic acid in women of childbearing age. Am J Clin Nutr. PMID 16825690
• Centers for Disease Control and Prevention. 2026 (July 16). MTHFR gene variant and folic acid facts.
• Obeid R, Holzgreve W, Pietrzik K. 2013. Is 5-methyltetrahydrofolate an alternative to folic acid for the prevention of neural tube defects? J Perinat Med. PMID 23482308
• MRC Vitamin Study Research Group. 1991. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet. PMID 1677062
• Czeizel AE, Dudás I. 1992. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med. PMID 1307234
• Williams J, Mai CT, Mulinare J, et al. 2015. Updated estimates of neural tube defects prevented by mandatory folic acid fortification — United States, 1995–2011. MMWR Morb Mortal Wkly Rep. PMID 25590678
• US Preventive Services Task Force; Barry MJ, Nicholson WK, Silverstein M, et al. 2023. Folic acid supplementation to prevent neural tube defects: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. PMID 37526713
• Skavinska O, Rossokha Z, Stefanyshyn V, et al. 2026. Comparative analysis of treatment with folate forms in clinical practice. Nutr Rev. PMID 41277701
• EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). 2022. Conversion of calcium-l-methylfolate and (6S)-5-methyltetrahydrofolic acid glucosamine salt into dietary folate equivalents. EFSA Journal 20(8):e07452. doi:10.2903/j.efsa.2022.7452 (PMID 36034319)
• EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). 2023. Scientific opinion on the tolerable upper intake level for folate. EFSA Journal 21(11):e08353. doi:10.2903/j.efsa.2023.8353 (PMID 37965303)
• Miller JW, Smith A, Troen AM, et al. 2024. Excess folic acid and vitamin B12 deficiency: clinical implications? Food Nutr Bull. PMID 38987872
• Pfeiffer CM, Sternberg MR, Fazili Z, et al. 2015. Unmetabolized folic acid is detected in nearly all serum samples from US children, adolescents, and adults. J Nutr. PMID 25733468
• Papakostas GI, Shelton RC, Zajecka JM, et al. 2012. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. PMID 23212058
• Shea B, Swinden MV, Tanjong Ghogomu E, et al. 2013. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. PMID 23728635
• Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. 2000. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. PMID 11096168